Produção Nacional
Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital
2013; Elsevier BV; Linguagem: Inglês
10.5581/1516-8484.20130053
ISSN1806-0870
AutoresSamuel Roosevelt Campos dos Reis, Acy Telles de Souza Quixadá, Sammara Tavares Nunes, Danielle Maria Camelo Cid, Jacqueline Holanda de Souza, Clara Maria Bastos Eloy da Costa, Carolina Bizelli Silveira, David Antonio Camelo Cid, Mariana Fátima Cabral de Oliveira,
Tópico(s)Eosinophilic Disorders and Syndromes
ResumoThis is a retrospective and exploratory study.The study period was from January 2001 to January 2011.Participation in the study was limited to Ph chromosome positive CML patients Objective: The aim of this study was to identify the reasons for failure in adherence to imatinib mesylate treatment in chronic myeloid leukemia.Methods: A retrospective review was performed of 100 non-electronic records of patients with Ph + chronic myeloid leukemia treated with imatinib mesylate.The study period was from January 2001 to January 2011.Data were analyzed by Chi-Square and Correspondence analysis using the Statistical Analysis System software package.Results: At the beginning of treatment 41% of patients were in advanced stages of the disease.The unavailability of the drug (44.8%) and myelotoxicity (25.7%) were the most frequent reasons for interruption.The adherence rate was ≤ 90% in 47% of the cases.The low adherence influenced the cytogenetic response (p-value = 0.020) and molecular response (p-value = 0.001).Very high adherence (≥ 95%) induced complete cytogenetic response, major cytogenetic response and major molecular response. Conclusion:The population of this study obtained lower-than-expected therapeutic responses compared to other studies.
Referência(s)